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Background: Impaired regulation of extracellular matrix remodeling by matrix metalloproteinases (MMPs) and
tissue inhibitor of metalloproteinase (TIMP) may contribute to vascular complications in patients with type 1
diabetes. We investigated associations between plasma MMP-1, −2, −3, −9, −10 and TIMP-1, and cardiovascular
disease (CVD) or microvascular complications in type 1 diabetic patients. We also evaluated to which extent these
associations could be explained by low-grade inflammation (LGI) or endothelial dysfunction (ED).
Methods: 493 type 1 diabetes patients (39.5 ± 9.9 years old, 51% men) from the EURODIAB Prospective
Complications Study were included. Linear regression analysis was applied to investigate differences in plasma
levels of MMP-1, −2, −3, −9, −10, and TIMP-1 between patients with and without CVD, albuminuria or retinopathy.
All analyses were adjusted for age, sex, duration of diabetes, Hba1c and additionally for other cardiovascular risk
factors including LGI and ED.
Results: Patients with CVD (n = 118) showed significantly higher levels of TIMP-1 [β = 0.32 SD (95%CI: 0.12; 0.52)],
but not of MMPs, than patients without CVD (n = 375). Higher plasma levels of MMP-2, MMP-3, MMP-10 and TIMP-1
were associated with higher levels of albuminuria (p-trends were 0.028, 0.004, 0.005 and 0.001, respectively). Severity
of retinopathy was significantly associated with higher levels of MMP-2 (p-trend = 0.017). These associations
remained significant after further adjustment for markers of LGI and ED.
Conclusions: These data support the hypothesis that impaired regulation of matrix remodeling by actions of MMP-2, -3
and-10 and TIMP-1 contributes to the pathogenesis of vascular complications in type 1 diabetes.
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Type 1 diabetes is associated with an increased risk of
macro- and microvascular disease [1,2]. The exact mecha-
nisms leading to vascular damage in type 1 diabetes have
not been fully established [3], but impaired regulation of
extracellular matrix (ECM) remodeling by matrix metallo-
proteinases (MMPs) may contribute to the development
of vascular complications [4,5]. Increased MMP activity
has been associated with increased matrix turnover and
potentially to pathological reorganization of the ECM in
atherosclerosis, aneurysm formation, plaque disruption [4]
and, in diabetic nephropathy, to glomerular basement
membrane thickening [5].
MMPs are a group of zinc- and calcium-dependent en-
dopeptidases, which degrade and rebuild proteins of the
ECM, such as collagen, elastin, gelatin and casein [6].
Thus far, more than 20 different MMPs have been identi-
fied, which, according to their various functions, can
be divided into collagenases (e.g. MMP-1), gelatinases
(MMP-2 and MMP-9), stromelysines (e.g. MMP-3 and
MMP-10), matrilysines, and others. These enzymes can be
excreted by various cells (e.g. fibroblasts, endothelial cells,
monocytes and macrophages) or can be incorporated in
the cellular membrane. Tissue inhibitors of metallopro-
teinases (TIMP-1-4) and α2-macroglobulin inhibit the
action of MMPs [6].
Plasma levels of MMPs have been observed to be higher
in individuals with type 1 diabetes, compared to controls
[7-9]. The association between circulating MMPs and
macrovascular disease in patients with type 1 diabetes has
not been investigated, while studies on the associations be-
tween MMP levels and microvascular complications seem
contradictory. For example, high levels of serum MMP-9
and a high MMP-9-to-TIMP ratio have been related to
retinopathy [10], and high levels of plasma MMP-10 have
been associated with nephropathy and proliferative retin-
opathy [8]. In contrast, other studies did not show signifi-
cant associations between plasma levels of MMP-2, -9 or
TIMP-1 and microvascular complications [7,11]. In fact,
most studies were rather small [7,9-11] or limited to only
one or two MMPs [7-11]. In one large study of 269 type 1
diabetes patients and 269 non-diabetic controls [8],
plasma MMP-10 was associated with nephropathy and
proliferative retinopathy. However, plasma TIMP was not
measured, whereas this may be of importance as MMP-10
activity is dependent on the amount of inhibitors. Never-
theless, in type 1 diabetes, hyperglycaemia, low-grade in-
flammation (LGI) and endothelial dysfunction (ED) have
been found to be associated with higher plasma and tissue
levels of MMPs and TIMP [5,9,12], and LGI and ED are
consistently associated with macro- and microvascular
complications [13-15].
In view of these considerations, we hypothesized that
high plasma levels of MMPs and TIMP are related tomacro- and microvascular complications in individuals
with type 1 diabetes, possibly through associations with
LGI and ED. We investigated these hypotheses in a
cross-sectional study of patients with type 1 diabetes, in
whom we assessed macro- and microvascular disease
and measured plasma levels of MMP-1, −2, −3, −9, −10
and TIMP-1, as well as biomarkers of LGI and ED.Methods
Study population
In this analysis, data were used from the EURODIAB
Prospective Complications Study, a European pro-
spective cohort study that has been described in detail
previously [16,17].
In brief, baseline inclusion was performed between
1989 and 1991 in 3,250 patients with type 1 diabetes. In-
clusion criteria were defined as a clinical diagnosis of
type 1 diabetes before the age of 36 years, and require-
ment of continuous insulin therapy within the first year
of diagnosis. Patients aged between 15 and 60 years were
recruited from 31 centres in 16 European countries.
Sample selection was stratified by sex, age group and
duration of diabetes to ensure sufficient representation
of all categories. These patients were invited for a
follow-up visit 7–9 years after baseline enrolment. Of
the 3,250 included patients, 1,880 (57.8%) returned for
re-examination. At follow-up, a cross-sectional nested
case–control study was performed in a subset of patients
(n = 543). Cases (n = 348) were those with one or more
complications and controls (n = 195) were those with no
evidence of complications [18]. This type 1 diabetic pa-
tient control group was used to investigate differences in
plasma levels of MMPs and TIMP-1 compared with type
1 diabetic patients with vascular complications. For the
current analyses, clinical data, plasma samples for ana-
lysis of MMPs and TIMP-1 and information about po-
tential confounders and mediators were available in 493
of these 543 patients. The study was approved by the
local Ethics Committee at each centre and all patients
gave informed consent.Main determinants
Concentrations of MMPs and TIMP-1 were determined
in plasma samples that were stored at −80°C after collec-
tion and in our laboratory until analyses and they were
never thawed previously. Plasma levels of MMP-1,
MMP-2, MMP-3, MMP-9, MMP-10 and TIMP-1 were
measured using a commercially available enzyme-linked
immunosorbent assay (ELISA) kit [Human MMP 3-Plex
Kit (for MMP-1, −3 and −9), Human MMP-2-Plex Kit
(for MMP-2 and -10) and Human TIMP-1 Kit, MSD,
Rockville, United States of America] according to the
manufacturer’s protocol. Plasma samples of 10, 25 and
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2-plex kit and TIMP-1 kit, respectively. The MMPs were
detected in both a pro- and an active form. TIMP-1 was
detected only in the active form. The intra- and inter-
assay coefficients of variation were 7.0% and 8.0% for
MMP-1, 4.5% and 5.9% for MMP-2, 8.4% and 12.3% for
MMP-3, 5.3% and 8.9% for MMP-9, 4.4% and 9.7% for
MMP-10, and 4.3% and 5.2%for TIMP-1, respectively.
Main outcomes
Macrovascular disease
Cardiovascular disease (CVD) was defined as a cardio-
vascular event in a patient’s medical history, including
myocardial infarction, angina, coronary artery bypass
graft, stroke or ischaemic changes in a centrally
Minnesota-coded ECG [19].
Microvascular disease
Albumin excretion rates were measured from duplicate
24-hour urine collections [17]. Micro- and macroalbumi-
nuria were defined as an albumin excretion rate between
20 and 200 μg/min, or above 200 μg/min, respectively. We
also estimated the glomerular filtration rate (eGFR) using
the Chronic Kidney Disease Epidemiology Collaboration
(CKD-EPI) equation [20].
Retinopathy was assessed from retinal photographs ac-
cording to the EURODIAB protocol; non-proliferative ret-
inopathy was defined as the presence of one or more
microaneurysms, hemorrhages, and/or hard exudates. Pro-
liferative retinopathy was defined as presence of any new
vessels, fibrous proliferations, pre-retinal haemorrhages,
vitreous hemorrhages or photocoagulation scars [21].
Other variables
Apart from demographic data, additional information
about medication, smoking history, systolic blood pres-
sure and duration of diabetes was collected. Body weight
and height were measured in patients wearing indoor
clothing without shoes. With these values body mass
index (BMI) was calculated. Fasting blood samples were
taken for measurements of lipid profile and glycemic
control. Cholesterol and triglyceride levels were mea-
sured by enzymatic colorimetric tests [22], HDL was
measured directly [23]. Friedewald’s formula was used to
calculate LDL levels [24]. Glycated hemoglobin (HbA1c)
was measured by a latex-enhanced turbidimetric im-
munoassay (Roche Products, Welwyn Garden City, UK).
The reference range for this assay was 4.2-6.2%.
Markers of LGI
Plasma levels of C-reactive protein (CRP) were measured
with a highly sensitive ELISA, developed and validated
in our own laboratory [18]. Plasma levels of interleukin-
6 (IL-6) and tumor necrosis factor-α (TNF-α) weremeasured using commercially available ELISA kits (R&D
Systems, Oxon, U.K.) [18]. Intra- and inter-assay coeffi-
cients of variation were 3.9 and 8.7% for CRP, 4.5 and
9.0% for IL-6, and 7.3 and 8.5% for TNF-α, respectively.
Markers of ED
Plasma soluble E-selectin (sE-selectin) and soluble vascu-
lar cell adhesion molecule-1 (sVCAM-1) were measured
by sandwich enzyme immunoassays (R&D Systems,
OXON, U.K.) in duplicate. Individual mean values of the
duplicates were used in the ED scores. Intra- and inter-
assay coefficients of variation were 2.1% and 3.1% for sE-
selectin, and 4.0% and 9.1% for sVCAM-1, respectively.
Statistical analyses
All analyses were performed using the Statistical Package
for Social Sciences (SPSS), version 20 (IBM Corporation,
Armonk, NY, USA). Log transformation was performed
for variables with a skewed distribution (triglycerides,
serum creatinine, eGFR, MMP-1, MMP-2, MMP-3,
MMP-9, MMP-10, CRP, IL-6 and TNF-α). Student’s
t- or Chi-Square tests were performed for comparisons
of characteristics between individuals with and without
vascular complications, as appropriate.
Linear regression analyses were performed to examine
the extent to which plasma levels of MMP-1, MMP-2,
MMP-3, MMP-9, MMP-10 and TIMP-1 differed between
individuals with and without CVD or microvascular com-
plications as well as to test for linear trends in plasma
levels of MMPs and TIMP-1 between both micro- and
macroalbuminuria and between non-proliferative and pro-
liferative retinopathy. Results of these analyses are pre-
sented as standardized regression coefficients to enable
comparison of the magnitude of the associations. We have
only investigated single MMPs and TIMP-1 in the analyses
and have not adjusted for the presence of others, because
each MMP has its own substrate specificity and actions.
Analyses were adjusted for age, sex, duration of diabetes
and HbA1c (model 1). Further adjustments were made for
LDL, HDL, systolic blood pressure, eGFR, antihypertensive
medication, triglycerides, BMI and smoking, and for the
presence of CVD, albuminuria and/or retinopathy, as ap-
propriate (model 2). Markers of ED (model 3) and LGI
(model 4) were subsequently added to this model to ex-
plore whether the association between plasma levels of
MMPs and TIMP-1 on the one hand and CVD and micro-
vascular complications on the other (if any) were explained
(i.e., potentially mediated) by LGI and/or ED. Markers of
LGI were comprised into an overall LGI z-score by com-
puting a z-score after averaging the z-scores of lnCRP,
lnIL-6 and lnTNF-α. ED z-scores were expressed after
averaging of the z-scores of sVCAM-1 and sE-selectin. A
z-score represents the difference between the individual
biomarker score and the mean value in the population,
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population. This enables comparison of markers expressed
in different units. The two scores represent a more robust
value of the individual’s levels of LGI and ED, as they re-
duce the influence of biological variability expected when
LGI and ED should be characterized by levels of each bio-
marker separately [25].
Results
Patients’ characteristics
Table 1 shows the characteristics of patients with or
without vascular complications. Patients with vascularTable 1 Clinical characteristics of the study population
Vascular com
(n = 306)
Age (years) 41.6 (10.4)
Sex (male/female, %) 54/46
BMI (kg/m2) 24.8 (3.5)
HbA1c (%) 9.0 (1.6)
HbA1c (mmol/mol) 75 (17.4)
Duration of diabetes (years) 25.2 (8.9)
LDL cholesterol (mmol/l) 3.30 (1.06)
HDL cholesterol (mmol/l) 1.59 (0.42)
Triglycerides (mmol/l) 1.13 [0.84-1.58
Smoking (no/former/current) (%) 36/31/33
Systolic blood pressure (mmHg) 127 (21)
Diastolic blood pressure (mmHg) 75 (12)
Serum creatinine (μmol/l) 76.0 [68.0-90.0
eGFR (ml/min/1.73 m2) 95.7 [79.0-107
Cardiovascular disease (%) 38.6
Albuminuria (normo-/micro-/macro-)(%) 37.9/25.2/36.9
Retinopathy (no/background/proliferative) (%) 11.4/40.9/47.7
Antihypertensive medication (%) 45.4
ACE-inhibitor (%) 37.6
MMP-1 (ng/ml) 12.8 [7.0-19.9]
MMP-2 (ng/ml) 110 [100–120]
MMP-3 (ng/ml) 17.8 [11.2-28.3
MMP-9 (ng/ml) 122 [81–195]
MMP-10 (pg/ml) 1285 [942–193
TIMP-1 (ng/ml) 313 (100)
C-reactive protein (mg/l) 1.28 [0.46-2.68
Interleukin-6 (pg/ml) 2.12 [1.35-3.86
Tumor necrosis factor-α (pg/ml) 3.16 [2.33-4.42
Soluble e-selectin (ng/ml) 35.7 (16.6)
Soluble vascular cell adhesion molecule-1 (ng/ml) 435 (144)
Data are presented as means (standard deviation), median [inter-quartile range], or
Vascular complication: presence of previous CVD, macroalbuminuria, or proliferative
retinopathy; BMI, body mass index; HbA1c, glycated hemoglobin; LDL, low-density
rate by CKD-EPI formula; MMP, matrix metalloproteinase; TIMP-1, tissue inhibitor ofcomplications were characterized by higher age, BMI
and systolic blood pressure. Levels of HbA1c, LDL, tri-
glycerides, MMP-1, MMP-2, MMP-3, MMP-9, MMP-10,
TIMP-1 and markers of LGI and ED were significantly
higher in individuals with vascular complications com-
pared to those without.
Associations between MMPs, TIMP-1 and cardiovascular
disease
Significantly higher plasma levels of TIMP-1 [β = 0.27
SD (95%CI: 0.06; 0.48)] were observed in individuals
with CVD (n = 118) as compared to those without, afterplications No vascular complications p-value
(n = 187)
36.1 (8.1) <0.001
46/54 0.096
23.9 (2.6) <0.001
7.7 (1.3) <0.001
61 (14.1) <0.001
15.5 (7.0) <0.001
2.88 (0.93) <0.001
1.68 (0.45) 0.032
] 0.85 [0.67-1.09] <0.001
46/26/28 0.047
115 (13) <0.001
73 (10) 0.085
] 71.0 [64.0-79.0] <0.001
.9] 107.9 [97.2-115.6] <0.001
- -
- -
- -
5.9 <0.001
4.3 <0.001
10.8 [5.9-16.5] 0.006
103 [96–110] <0.001
] 12.9 [8.3-19.6] <0.001
110 [66–172] 0.023
1] 1077 [790–1635] <0.001
256 (74) <0.001
] 0.71 [0.35-1.80] <0.001
] 1.57 [1.06-2.50] <0.001
] 2.22 [1.68-2.85] <0.001
31.1 (11.1) <0.001
378 (104) <0.001
percentages, as appropriate.
retinopathy or the combination of microalbuminuria and non-proliferative
lipoprotein; HDL, high-density lipoprotein; eGFR, estimated glomerular filtration
metalloproteinase-1.
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(Additional file 1: Table S1, Model 1). The association
became even stronger [0.32 (0.12; 0.52)] after further ad-
justment for other cardiovascular risk factors, albumin-
uria and retinopathy (Figure 1; Additional file 1: Table
S1, Model 2). In contrast, MMP-1, MMP-2, MMP-3,
MMP-9 and MMP-10 did not differ between groups.
Associations between MMPs, TIMP-1 and albuminuria
Patients with microalbuminuria (n = 77) showed signifi-
cantly higher plasma levels of MMP-2 compared to pa-
tients with normal urinary albumin excretion after
adjustment for cardiovascular risk factors and other vascu-
lar complications [0.32 (0.03; 0.61)] (Figure 2A; Additional
file 2: Table S2, Model 2). Macroalbuminuria (n = 113),
compared to normoalbuminuria, was associated with even
higher levels of MMP-2 [0.38 (0.10; 0.66)] (Figure 2A;
Additional file 2: Table S2). In this group, additionally,
higher plasma levels of MMP-3 [0.33 (0.11; 0.54)],
MMP-10 [0.38 (0.08; 0.67)] and TIMP-1 [0.45 (0.18;
0.71)] were found. Significant associations with the
degree of albuminuria (normo- vs. micro- vs. macroal-
buminuria) were observed for higher plasma levels of
MMP-2 (p-trend = 0.028), MMP-3 (p-trend = 0.004),
MMP-10 (p-trend = 0.005) and TIMP-1 (p-trend = 0.001)
(Figure 2A).
Associations between MMPs, TIMP-1 and retinopathy
Proliferative retinopathy (n = 146) was associated with
higher levels of MMP-2 [0.71 (0.45; 0.96)], MMP-3 [0.49
(0.28; 0.70)], MMP-10 [0.39 (0.11; 0.66)] and TIMP-1Figure 1 Associations between plasma levels of MMPs, TIMP-1
and CVD. Point estimates and 95% confidence intervals show the
difference in plasma levels of lnMMP or TIMP-1 (in SD) in patients
with vs. those without CVD resulting from a multivariable regression
model including all cardiovascular risk factors, albuminuria and
retinopathy (model 2).[0.54 (0.28; 0.81)] after adjustment for age, sex, duration
of diabetes and HbA1c (Additional file 3: Table S3,
Model 1). However, after further adjustment for the
other cardiovascular risk factors, CVD and albuminuria,
only MMP-2 [0.36 (0.06; 0.66)] remained significantly
higher in patients with proliferative retinopathy vs. those
without retinopathy (Figure 2B; Additional file 3: Table
S3, Model 2). In addition, a significant trend across the
severity of retinopathy was observed for increasing
plasma levels of MMP-2 (p-trend = 0.017).
In contrast, non-proliferative retinopathy (n = 125) was
not significantly associated with higher plasma levels of
MMPs or TIMP-1 (Figure 2B; Additional file 3: Table S3).
Associations of MMPs and TIMP-1 with LGI and ED
Associations between MMPs and TIMP-1 and the indi-
vidual markers of LGI and ED are shown in Additional
file 4: Table S4. After adjustment for all cardiovascular
risk factors (model 2), MMP-1, −3, −9, −10, and TIMP-
1, but not MMP-2, were positively and significantly asso-
ciated with the LGI score. In addition, MMP-2, MMP-10
and TIMP-1 were positively and significantly associated
with the ED score (Table 2, model 2). However, signifi-
cant associations between plasma levels of MMPs and
TIMP-1 on the one hand and CVD, albuminuria and
retinopathy on the other hand were largely independent
of LGI and ED, as these associations remained signifi-
cant after adding the LGI and/or ED score to the model
(Additional file 1: Table S1, Additional file 2: Table S2
and Additional file 3: Table S3; Models 3, 4 and 5).
Additional analyses
Adding use of ACE inhibitors specifically versus antihy-
pertensive medication in general as covariable to our
models, did not materially influence the results. Simi-
larly, adjustment for urinary albumin excretion rate in-
stead of albuminuria status and waist-hip-ratio instead
of BMI did not change our results (data not shown). We
have not included adjustment for TIMP-1 in model 2 in
the main analyses between plasma levels of MMPs and
vascular complications, because TIMP-1 levels are influ-
enced by all MMPs and not just by one MMP. There-
fore, we have also not analyzed associations between
MMP/TIMP-1 ratios and vascular complications. How-
ever, additional adjustment in model 2 for TIMP-1 levels
did also not materially influence our results.
In the relationship between MMPs, TIMP and vascular
complications, eGFR (a marker of renal dysfunction) can
be considered as a potential confounder or mediator. If
eGFR should be a mediator rather than a confounder,
models including eGFR may be overadjusted. We there-
fore reanalyzed the data without adjustment for eGFR;
results were generally similar to models with such ad-
justment (data not shown).
Figure 2 Associations between plasma levels of MMPs, TIMP-1 and microvascular complications. Point estimates and 95% confidence intervals
show the difference in plasma levels of lnMMP or TIMP-1 (in SD) in patients with vs. those without microvascular complications resulting from
a multivariable regression model including all cardiovascular risk factors and the other vascular complications (model 2). A, differences in
micro- (grey bars) or macroalbuminuria (black bars) compared to normoalbuminuria; B, differences in non-proliferative (grey bars) and proliferative
retinopathy (black bars) compared to no retinopathy. P-trend indicates the statistical significance of the associations between plasma levels of MMPs or
TIMP and the degrees of albuminuria (normo- vs. micro- vs. macroalbuminuria) or retinopathy (no vs. non-proliferative vs. proliferative retinopathy).
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This is the first study that comprehensively assessed asso-
ciations of MMPs and TIMP-1 with long-term complica-
tions in type 1 diabetes. In a group of 493 patients with
and without diabetes complications, we found that high
plasma levels of TIMP-1 were associated with CVD. In
addition, MMP-2, -3 and -10, and TIMP-1 levels were
associated with macroalbuminuria, and MMP-2 was asso-
ciated with proliferative retinopathy. All these associations
remained significant after adjustment for cardiovascularrisk factors, prevalence of other vascular complications
and markers of LGI and ED.
MMPs, TIMP-1 and CVD
Prevalent CVD was associated with higher plasma levels
of TIMP-1, but not of MMP-1, −2, −3, −9 and −10. In
accordance, significantly higher levels of plasma TIMP-1
have been previously observed in two studies in type 2
diabetic patients with a history of coronary artery disease
[26,27]. In addition, in a large prospective cohort study
Table 2 Associations between lnMMP-1, −2, −3, −9, −10 and TIMP-1 and the LGI and ED scores
Inflammation (z-score) Endothelial dysfunction (z-score)
Model β 95% CI p-value β 95% CI p-value
MMP-1 1 0.07 −0.02;0.15 0.112 0.00 −0.09;0.09 0.998
2 0.08 0.00;0.16 0.047 0.00 −0.09;0.08 0.987
3 0.08 −0.00;0.15 0.062 −0.01 −0.09;0.08 0.834
MMP-2 1 0.10 0.01;0.18 0.032 0.19 0.10;0.27 <0.001
2 0.03 −0.06;0.12 0.526 0.14 0.04;0.23 0.004
3 0.00 −0.08;0.09 0.950 0.13 0.04;0.22 0.006
MMP-3 1 0.26 0.16;0.36 <0.001 0.08 −0.03;0.19 0.137
2 0.19 0.09;0.30 0.001 −0.02 −0.14;0.10 0.715
3 0.17 0.06;0.28 0.003 −0.04 −0.16;0.08 0.474
MMP-9 1 0.16 0.08;0.25 <0.001 −0.02 −0.11;0.06 0.592
2 0.17 0.09;0.24 <0.001 −0.02 −0.10;0.07 0.718
3 0.16 0.08;0.24 <0.001 −0.02 −0.10;0.06 0.577
MMP-10 1 0.24 0.16;0.32 <0.001 0.13 0.04;0.21 0.003
2 0.22 0.14;0.30 <0.001 0.11 0.02;0.20 0.019
3 0.21 0.13;0.30 <0.001 0.10 0.01;0.19 0.029
TIMP-1 1 0.34 0.27;0.43 <0.001 0.25 0.17;0.33 <0.001
2 0.29 0.21;0.38 <0.001 0.21 0.12;0.30 <0.001
3 0.28 0.20;0.37 <0.001 0.20 0.11;0.29 <0.001
β, standardized regression coefficient: indicates increase in the low-grade inflammation and endothelial dysfunction score (in SDs) per 1 SD increase in
lnMMP-1, −2, −3, −9, −10 or TIMP-1. CI: confidence interval. MMP: matrix metalloproteinase.
Model 1: adjusted for age, sex, duration of diabetes and HbA1c.
Model 2: model 1 + BMI, triglycerides, LDL, HDL, systolic blood pressure, eGFR, smoking and antihypertensive medication.
Model 3: model 2 + CVD, albuminuria and retinopathy.
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betes, increased plasma TIMP-1 levels, measured six
months after myocardial infarction, was significantly as-
sociated with left ventricular remodeling and adverse
outcomes [28]. In the current study on individuals with
type 1 diabetes, measurements of plasma TIMP-1 were,
by its cross-sectional design, performed 1 month to
10 years after the cardiovascular event. Although we
cannot prove a relationship between elevated plasma
levels of TIMP-1 and new cardiovascular events, TIMP-
1 may be a marker for abnormal regulation of matrix re-
modeling after a cardiovascular event. This is supported
by studies in animal models showing elevation of plasma
TIMP-1 in type 1 diabetic minipigs with left ventricular
hypertrophy, increased cardiac fibrosis and cardiac dys-
function [29].
MMPs, TIMP-1 and albuminuria
Plasma levels of MMP-2 were significantly higher in
both micro- and macroalbuminuric patients compared
to those with normoalbuminuria. In contrast, a previous
study in type 1 diabetic patients did not show increased
levels of MMP-2 in microalbuminuric vs. normoalbumi-
nuric individuals [7]. This discrepancy may be explained
by the very small sample size (n = 12) of that study [7].Thus far, no studies have been reported regarding
plasma MMP-3 and diabetic nephropathy in humans or
animals. Our study is the first study showing that higher
plasma levels of MMP-3 are associated with increasing
levels of albuminuria. In accordance with our study, in
type 2 diabetic patients, high interstitial MMP-3 mRNA
expression was associated with higher degrees of inter-
stitial injury [30]. The increased plasma MMP-3 could
therefore potentially originate from the renal intersti-
tium. This finding may be biologically explained by the
fact that type IV collagen, one of the major substrates of
proteolysis by MMP-3, is an important component of
the basal lamina of the glomerular basement membrane,
Bowman’s capsule, and of the basal membranes of renal
tubules and vessels [31]. MMP-3-dependent type IV colla-
gen proteolysis therefore constitutes a potential explan-
ation for the current observation of a strong association
between MMP-3 and albuminuria.
In addition, higher plasma MMP-10 levels were sig-
nificantly associated with macroalbuminuria in our
study. This result is in full agreement with a recent
study [8] in patients with type 1 diabetes, in which a
higher plasma level of MMP-10 was associated with
diabetic nephropathy independently of classical risk
factors. In addition, MMP-10 knockout (streptozotocin
Peeters et al. Cardiovascular Diabetology  (2015) 14:31 Page 8 of 10(STZ)-induced) diabetic mice showed lower renal
mesangial cell expansion and lower renal macrophage
influx compared to wildtype diabetic mice [8], suggesting
that MMP-10 may be involved in the onset of diabetic
nephropathy.
Besides MMP-2, -3, and -10, TIMP-1 was also associated
with macroalbuminuria. This association was also ob-
served in one-sided nephrectomized type 1 diabetic rats
compared to non-diabetic controls [32]. These results re-
flect a possible role for TIMP-1 in increased renal fibrosis
in early diabetic nephropathy.MMPs, TIMP-1 and retinopathy
Plasma MMP-2 levels showed a significant positive as-
sociation with proliferative retinopathy. Salzmann et al.
[33] showed an overall increase of different MMPs (−2,
−3 and −9) and TIMP-1 in specimens of retinal tissue
of patients with proliferative diabetic retinopathy com-
pared to retinal tissue of patients without diabetes.
Also, increased retinal levels of MMP-2 were found in
rats and mice with STZ-induced diabetes compared to
non-diabetic controls [34]. Our current clinical results,
supported by the relatively scarce literature, indicate
that MMP-2 may play a role the pathogenesis of prolif-
erative diabetic retinopathy. In addition, the study by
Toni et al. [8] has shown a significant association be-
tween plasma MMP-10 and proliferative retinopathy,
which is in accordance with our current findings in the
minimally adjusted model (including age, sex, duration
of diabetes and HbA1c). However, this was no longer
significant after additional adjustment for cardiovascular
risk factors and the presence of CVD and albuminuria.
Since Toni et al. did not adjust for the presence of other
vascular complications, this could explain the observed
difference between their and our study.
We did not find a significant association of plasma
MMPs or TIMP-1 levels with non-proliferative retinop-
athy. This is in contrast with the results of the study of
Jacqueminet et al. [10], in which increased serum MMP-
9 levels were shown in patients with type 1 diabetes with
minimal to moderate retinopathy (n = 14) compared to
diabetic patients without retinopathy and non-diabetic
controls. Possibly the serum measurement does not truly
reflect the circulating concentration of MMPs and
TIMPs compared to the plasma measurement [35]. In
addition, potential confounders may not have been fully
addressed in this earlier study, but were shown to be of
importance in the current study. In fact, also the current
study showed a significant association between plasma
MMP-9 levels and the presence of non-proliferative ret-
inopathy in the crude model [standardized β = 0.22
(0.00;0.44)], but this was attenuated after adjustment for
confounding.MMPs, TIMP-1, low-grade inflammation (LGI) and endothelial
dysfunction (ED)
In our study, all MMPs, except MMP-2, were signifi-
cantly associated with markers of low-grade inflamma-
tion (Table 2, model 2). Indeed, it is well known that
MMP-2 has a more potent anti-inflammatory effect
compared to other MMPs, which may be attributable to
the fact that monocyte chemo-attractant protein-3
(MCP-3) is an important substrate of MMP-2. The
product of MCP-3 after cleavage by MMP-2 antagonizes
the effect of MCP-3 on the chemokine receptors-1, −2
and −3 and may thereby attenuate the inflammatory re-
sponse [36]. Although MMP-1 and MMP-3 are known
to cleave MCP-1, −2 and −4, the antagonistic effects of
the cleaved products on inflammation are minimal, be-
cause of lower affinity for the chemokine receptors [37].
MMPs can be activated and up-regulated by mediators
of inflammation, but also have an intrinsic effect on the
inflammatory response [38]. Although the exact role of
MMPs in the inflammatory cascade remains incom-
pletely understood, our results suggest that associations
of MMPs and TIMP-1 with complications of type 1 dia-
betes are unlikely to be explained by LGI.
MMP-2, MMP-10 and TIMP-1 were associated with
markers of ED. These findings are in line with literature
demonstrating that MMP-2 is able to degrade occludin,
a tight junction protein, in the blood retinal membrane
leading to increased vascular permeability [12], and
that MMP-10 can induce endothelial proteolysis in re-
sponse to CRP [39]. In addition, plasma TIMP-1 levels
are associated with endothelial cell migration [40].
Thus, associations between MMP and TIMP-1 levels
and ED are biologically plausible; nevertheless, our re-
sults suggest that associations of MMPs and TIMP-1
with complications of type 1 diabetes are unlikely to be
explained by ED.
Limitations
There are several limitations to our study. First, the
cross-sectional design only allows speculations on caus-
ality. We thus cannot exclude that increased levels of
plasma MMPs and TIMP-1 may be a result instead of a
cause of vascular complications. Second, circulating
levels of biomarkers may reflect specific organ injury,
but can also originate from other tissues. We adjusted
for other known vascular complications, but cannot rule
out that other causative factors may contribute and the
observed associations could therefore be underesti-
mated. In addition, MMP-1, −3, −10 and TIMP-1 have a
smaller molecular weight than albumin [41,42] and may
be filtered in the glomerulus, especially in albuminuric
patients, which may also have underestimated the asso-
ciations between these biomarkers and vascular compli-
cations. Third, plasma samples can be obtained easily
Peeters et al. Cardiovascular Diabetology  (2015) 14:31 Page 9 of 10and we thus used plasma levels to investigate the involve-
ment of MMPs and TIMP-1 in the pathogenesis of vascu-
lar complications in type 1 diabetes. However, we do not
know whether plasma markers truly reflect the local
pathological situation at the tissue level. Finally, our re-
sults suggest that associations of MMPs and TIMP-1 with
complications of type 1 diabetes are unlikely to be ex-
plained by LGI or ED, but we cannot exclude roles of LGI
or ED not reflected by the biomarkers we used.
Conclusion
In this study with type 1 diabetic patients, plasma MMP-2,
MMP-3, MMP-10 and TIMP-1 levels are associated with
macro- and microvascular complications and these associ-
ations were largely independent of LGI and ED. Further
(prospective) studies are warranted to elucidate the in-
volvement of MMPs and TIMPs in the development of
diabetic macro- and microvascular complications.
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